Get the Stockscreener App
176.37
1.05%
-1.88
After Hours:
176.37
Overview
News
Price History
Option Chain
Financials
Why BDX Down?
Discussions
Forecast
Stock Split
Dividend History
Becton Dickinson Co stock is traded at $176.37, with a volume of 4.69M.
It is down -1.05% in the last 24 hours and down -0.73% over the past month.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.
See More
Previous Close:
$178.25
Open:
$177.37
24h Volume:
4.69M
Relative Volume:
1.47
Market Cap:
$50.55B
Revenue:
$20.87B
Net Income/Loss:
$1.50B
P/E Ratio:
33.66
EPS:
5.24
Net Cash Flow:
$2.59B
1W Performance:
-4.83%
1M Performance:
-0.73%
6M Performance:
-28.77%
1Y Performance:
-25.27%
1-Day Range:
$174.49
$177.45
1-Week Range:
$174.49
$185.44
52-Week Range:
$163.33
$251.99
Becton Dickinson Co Stock (BDX) Company Profile
Name
Becton Dickinson Co
Sector
Industry
Phone
(201) 847-6800
Address
ONE BECTON DR, FRANKLIN LAKES
Compare BDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDX
Becton Dickinson Co
|
176.37 | 51.09B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ISRG
Intuitive Surgical Inc
|
483.12 | 172.46B | 9.15B | 2.61B | 1.99B | 7.17 |
|
ALC
Alcon Inc
|
87.87 | 43.30B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
279.20 | 39.87B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
239.26 | 17.20B | 2.90B | 467.20M | 306.90M | 6.37 |
Becton Dickinson Co Stock (BDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-25 | Downgrade | Citigroup | Buy → Neutral |
| May-02-25 | Downgrade | Goldman | Buy → Neutral |
| May-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-02-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-01-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-01-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-01-24 | Upgrade | Citigroup | Neutral → Buy |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-24-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| May-05-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-12-23 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jan-03-23 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-22 | Upgrade | Citigroup | Sell → Neutral |
| Jul-11-22 | Downgrade | Citigroup | Neutral → Sell |
| Jun-24-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-18-22 | Resumed | Raymond James | Mkt Perform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Dec-08-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-25-21 | Initiated | Barclays | Equal Weight |
| Dec-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-15-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jul-09-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-01-20 | Resumed | Goldman | Buy |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-07-20 | Downgrade | Cowen | Outperform → Market Perform |
| Feb-07-20 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Feb-07-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| Feb-06-20 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-08-20 | Downgrade | Barclays | Overweight → Equal Weight |
| May-13-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-07-18 | Initiated | Deutsche Bank | Buy |
| Oct-16-18 | Initiated | Barclays | Equal Weight |
| Jun-21-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-10-18 | Upgrade | Citigroup | Neutral → Buy |
| Jan-19-18 | Resumed | BofA/Merrill | Buy |
| Jan-05-18 | Upgrade | Citigroup | Sell → Neutral |
| Jan-05-18 | Initiated | KeyBanc Capital Mkts | Overweight |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Dec-29-17 | Reiterated | Deutsche Bank | Buy |
View All
Becton Dickinson Co Stock (BDX) Latest News
Covington resident wins $20 million in case against Becton Dickinson - The Covington News
Becton Dickinson Stock Dives 1.81% Amid 100.16% Volume Spike to $670M Ranking 199th in Market Activity as FDA Submission Drives Volatility - AInvest
Earnings Preview: Becton Dickinson (BDX) Q3 Earnings Expected to Decline - Yahoo Finance
BD receives FDA clearance for rapid point-of-care COVID-19 test By Investing.com - Investing.com South Africa
BD receives FDA clearance for rapid point-of-care COVID-19 test - Investing.com
Becton Dickinson receives FDA clearance for BD Veritor System for SARS-CoV-2 - TipRanks
BD's New FDA-Cleared COVID Test Delivers Results in Just 15 Minutes: What Healthcare Providers Should Know - Stock Titan
Former Masimo COO Bilal Muhsin Joins BD - Orange County Business Journal
Is Becton Dickinson and Company stock overvalued or undervaluedBuild wealth faster with high-performing stocks - jammulinksnews.com
What are analysts’ price targets for Becton Dickinson and Company in the next 12 monthsAchieve breakthrough financial growth - jammulinksnews.com
Becton Dickinson, BNY, Incyte, Duolingo, Jabil: Major Stock Sales Unveiled! - TipRanks
Earnings Preview: What To Expect From Becton, Dickinson And Company's Report - Barchart.com
Becton, Dickinson and Co’s PUREST Study: A New Era in Urine Management - TipRanks
Becton Dickinson Surges to 247th in Trading Volume with $477 Million in Shares Traded - AInvest
Becton, Dickinson and Company (BDX) Fell in Q2 as Earnings Fell Short of Expectations - Insider Monkey
What drives Becton Dickinson and Company stock priceBreakthrough financial growth - jammulinksnews.com
BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs - Quantisnow
Is Becton Dickinson and Company a good long term investmentBreakthrough financial growth - jammulinksnews.com
Becton Dickinson & Co To Go Ex-Dividend On September 8th, 2025 With 1.04 USD Dividend Per Share - 富途牛牛
Becton Dickinson Investors Seek Final OK Of $9M Deal - Law360
Top Executive Sells Over a Thousand Shares of Becton Dickinson Stock! - TipRanks
Becton Dickinson & Co Slips to 346th in Trading Volume Despite 3.39% Stock Price Gain - AInvest
BD Shareholders to Receive $4.16 Annual Dividend: Next Quarterly Payment Details Revealed - Stock Titan
Jim Cramer Notes Becton Dickinson Stock Recently “Finished in the Black” - MSN
Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5 Billion Deal - MSN
The Smartest Dividend Stock to Buy With $1,000 Right Now - The Motley Fool
Vascular Access Devices Company Evaluation Report 2025 | Becton Dickinson, Teleflex, and ICU Medical Strengthen Global Leadership Through Strategic Acquisitions and Product Innovation - Yahoo Finance
BD issues voluntary recall on certain Alaris infusion pump modules - MassDevice
BofA Securities Maintains Becton Dickinson & Co(BDX.US) With Hold Rating, Announces Target Price $190 - 富途牛牛
Estimating The Fair Value Of Becton, Dickinson and Company (NYSE:BDX) - 富途牛牛
Morgan Stanley Maintains Becton Dickinson & Co(BDX.US) With Buy Rating, Maintains Target Price $196 - 富途牛牛
BD issues update to recall of Alaris & BD Alaris pump modules - MarketScreener
BD to spin off biosciences, diagnostics businesses in $17.5B deal (updated) - NJBIZ
Waters to acquire BD flow cytometry business in a deal valued at $17.5 billion - C&EN
Becton Dickinson and : BD Issues Update to Voluntary Global Recall of Alaris™ and BD Alaris™ Pump Modules Serviced with Legacy Bezel Kit Assemblies - MarketScreener
How Do Investors Really Feel About Becton Dickinson? - 富途牛牛
Becton Dickinson stock holds steady as TD Cowen maintains $183 price target By Investing.com - Investing.com South Africa
Becton Dickinson stock holds steady as TD Cowen maintains $183 price target - Investing.com Nigeria
Becton, Dickinson & Co (BDX) Is Paying a $85M Settlement to Investors — Here’s How to Get Your Share - TradingView
Becton, Dickinson and Company (BDX) Traded Down on Weak Earnings - Insider Monkey
Becton, Dickinson and Company: A Solid Divestment For Its Bioscience And Diagnostics Business - Seeking Alpha
Becton Dickinson’s Hold Rating Amid Strategic Moves and Limited Immediate Upside - TipRanks
TD Cowen Initiates Becton Dickinson & Co(BDX.US) With Hold Rating, Announces Target Price $183 - 富途牛牛
Waters, BD’s Biosciences & Diagnostic Solutions to combine - Medical Buyer
A Big Move By Waters Corporation And Becton, Dickinson And Company (NYSE:WAT) - Seeking Alpha
William Blair Maintains Becton Dickinson & Co(BDX.US) With Hold Rating - 富途牛牛
BD’s biosciences & diagnostics unit in $17.5B merger with Waters - BioWorld MedTech
$17.5B Deal Combines Waters with BD’s Biosciences and Diagnostics Business - Genetic Engineering and Biotechnology News
Becton Dickinson Announces Reverse Morris Trust with Waters - TipRanks
Becton Dickinson Finds a Partner for Its Biosciences and Diagnostics Business in Waters - Morningstar
Milford’s Waters Corp. strikes $17.5 billion deal to merge with BD’s diagnostics unit - The Boston Globe
Becton Dickinson Co Stock (BDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):